Clinical trials: Cirrhosis, Liver
Liver Fibrosis, Pulmonary Fibrosis
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.
- Conditions
- Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
- Trial name
- NCT05180162
- Testing
- 68Ga-FAP-2286, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Hope
Primary Biliary Cirrhosis
Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid
Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations. Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver biochemistries and survival free…
- Trial name
- NCT02916641
- Testing
- Fuzhenghuayu, UDCA
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Decompensated Cirrhosis, Fecal Microbiota Transplantation
Fecal Microbiota Transplantation for Decompensated Cirrhosis
Imbalance of gut bacteria is suspected to play a key role driving the progression of cirrhosis and there is hope manipulation of these bacteria may be beneficial.
- Trial name
- FMTDC (NCT03014505)
- Testing
- FMT, traditional treatments
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Cirrhosis, Liver
Graft Inflow Modulation for Portal Hyper-perfusion in Live Donor Liver Transplantation
In this study, the investigators aim to prove that performing graft inflow modulation (GIM) in liver with portal hyper-perfusion is beneficial for early graft function postoperatively.
- Trial name
- NCT04252794
- Testing
- Splenic artery ligation, No intervention
- Where
- India
- Volunteers
- 75 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model.
- Conditions
- HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, HBV (Hepatitis B Virus)
- Trial name
- NCT07275554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Cirrhosis
To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)
In this randomized controlled trial , The patients who satisfy the below inclusion and exclusion criteria will be included and they will be randomised, according to 2 groups ( in total 110patients in each group) to receive either…
- Trial name
- NCT05060523
- Testing
- Tolvaptan Tablets, Midodrine Oral Tablet
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis C
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer…
- Trial name
- NCT00056862
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HDV
Thailand HDV Cohort
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special…
- Trial name
- NCT05350865
- Where
- 4 sites in Thailand
- Volunteers
- 3,296 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
- Trial name
- NCT04210245
- Testing
- aldafermin
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Decompensated Cirrhosis
Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.
Decompesated Cirrhosis is charecterised by decreased synthesis of both procoagulants and anticoagulants along with thrombocytopenia and a delicate balance exists bleeding and thrombosis in this condition.
- Trial name
- NCT05734001
- Testing
- ROTEM Tests, Conventional Haemostatic Tests
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cirrhosis, Esophageal and Gastric Varices
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding
The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Hemorrhage
- Trial name
- EoR-GEVB (NCT02964195)
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cirrhosis, Upper Gastrointestinal Bleeding
Prophylactic Antibiotics in Prevention of Spontaneous Bacterial Peritonitis in Compensated Liver Cirrhosis
timely short-term antibiotic prophylaxis is an essential step in the management of these patients . Prophylaxis must be instituted as early as variceal hemorrhage is suspected, and timely administration has been associated with a…
- Trial name
- NCT04711122
- Testing
- Third generation cephalosporin antibiotics
- Volunteers
- 80 people
- Sponsor
- Assiut University
Chronic Liver Disease and Cirrhosis
Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients…
- Trial name
- NCT07685353
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Liver, Splenectomy; Status
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection.
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension
- Trial name
- ELSDL (NCT05325437)
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Fibrosis Due to NASH
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT01672879)
- Testing
- SIM
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 259 people
- Sponsor
- Gilead Sciences
Cirrhosis, Liver, Diabetes Mellitus Risk
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation.
- Conditions
- Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
- Trial name
- NCT06950788
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Liver Fibrosis
Effect of Imatinib in Advance Liver Fibrosis Patients
When a recurrent, long-term injury and inflammation of the liver causes an excessive accumulation of damaged tissue, a dangerous condition called liver fibrosis develops. Most chronic liver diseases eventually lead to fibrosis.
- Trial name
- NCT05224128
- Testing
- Imatinib 200mg
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Research Institute for Gastroenterology and Liver Diseases (RIGLD)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.